Vistagen (VTGN) announced the appointment of Elissa Cote as Chief Corporate Development Officer. In this role, Cote will lead the evaluation of strategic opportunities to advance Vistagen’s pherine platform and cultivate prospective strategic partnerships. Cote previously served as fractional Chief Business Officer and strategic advisor to several biopharmaceutical clients and held senior roles at Mallinckrodt Pharmaceuticals, Sucampo Pharmaceuticals, and MedImmune. Vistagen also granted Cote an incentive option to purchase up to 150,000 shares of common stock.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VTGN:
- Vistagen Therapeutics’ Earnings Call Highlights Progress and Challenges
- Vistagen Therapeutics Reports Progress in Clinical Trials
- Closing Bell Movers: Futures extend decline amid Middle East tension
- VistaGen Files Prospectus to Raise $175 Million
- Vistagen reports FY25 EPS ($1.67), two estimates ($1.74)